药康生物: 第二届监事会第十一次会议决议公告

Group 1 - The company held its 10th meeting of the second Supervisory Board on May 22, 2025, with all three attending supervisors present, ensuring compliance with relevant laws and regulations [1][2] - The Supervisory Board approved the proposal to cancel part of the granted but unvested restricted stock, confirming it aligns with legal regulations and does not harm shareholder interests [1][2] - The proposal to adjust the grant price of the 2022 restricted stock incentive plan was also approved, following the completion of the company's 2023 and 2024 annual equity distributions [2][3] Group 2 - The Supervisory Board agreed that the second vesting period conditions for the initial grant of the 2022 restricted stock incentive plan have been met, allowing eligible participants to process the vesting of their restricted stock [3] - The adjustment of the 2025 stock appreciation rights incentive plan regarding the number of participants and quantity was approved, confirming compliance with relevant regulations [3][4] - The proposal to grant stock appreciation rights to eligible participants under the 2025 incentive plan was unanimously approved, with the grant date set for May 22, 2025 [4]